Suppr超能文献

伊拉地平或依那普利对盐敏感性高血压患者在低钠和高钠饮食摄入时血压的影响。MIST II试验研究者。

Effects of isradipine or enalapril on blood pressure in salt-sensitive hypertensives during low and high dietary salt intake. MIST II Trial Investigators.

作者信息

Chrysant S G, Weder A B, McCarron D A, Canossa-Terris M, Cohen J D, Gunter P A, Hamilton B P, Lewin A J, Mennella R F, Kirkegaard L W, Weir M R, Weinberger M H

机构信息

Oklahoma Cardiovascular and Hypertension Center and the University of Oklahoma, Oklahoma City, USA.

出版信息

Am J Hypertens. 2000 Nov;13(11):1180-8. doi: 10.1016/s0895-7061(00)01183-3.

Abstract

This large multicenter study, tested the antihypertensive effects of isradipine, a dihydropyridine calcium channel blocker and enalapril, an angiotensin-converting enzyme inhibitor, in salt-sensitive hypertensive patients under low and high salt intake diets. After a 3-week (weeks -9 to -6) of ad lib salt diet, those patients who had a sitting diastolic blood pressure (SDBP) of > or =95 but < or =115 mm Hg qualified to enter a 3-week (weeks -6 to -3) placebo run-in low salt diet (50 to 80 mmol Na+/day). Then high salt (200 to 250 mmol Na+/day) was added to the placebo treatment for 3 weeks (weeks -3 to 0). Those patients who demonstrated an increase in SDBP > or =5 mm Hg from the low to high salt diet were considered salt sensitive and were randomized into a 4-week (weeks 0 to 4) double-blind treatment period of either isradipine 2.5 to 10 mg twice a day, enalapril 2.5 to 20 mg twice a day, or placebo. Then they entered a 3-week (weeks 4 to 7) placebo washout phase of low salt diet (50 to 80 mmol Na+/day). After week 7 and while the low salt diet was continued the patients were restarted on their double-blind treatment for 4 more weeks (weeks 7 to 11) and the study was completed. Of 1,916 patients screened, 464 were randomized into the double-blind treatment phase and 397 completed the study. Both isradipine and enalapril decreased the sitting systolic blood pressure (SSBP) and SDBP during the high salt diet, to a similar degree, whereas enalapril caused a greater reduction in SSBP and SDBP than isradipine during the low salt diet (11.3 +/- 1.2/7.7 +/- 0.7 mm Hg v 7.7 +/- 0.9/4.8 +/- 0.6 mm Hg, mean +/- SEM, respectively, P < .02). Within drugs, the effect of isradipine on blood pressure (BP) was higher during the high than the low salt diet (14.9 +/- 1.5 v 7.6 +/- 1.3 mm Hg for SSBP and 10.1 +/- 0.6 v 4.8 +/- 0.9 mm Hg for SDBP, P < .001), but enalapril exerted a similar effect during both diets. Because salt restriction lowered both SSBP and SDBP, the lowest BP achieved with both drugs were during the salt restriction phase.

摘要

这项大型多中心研究,测试了二氢吡啶类钙通道阻滞剂伊拉地平以及血管紧张素转换酶抑制剂依那普利,在低盐和高盐饮食的盐敏感性高血压患者中的降压效果。在进行3周(第-9至-6周)的随意盐饮食后,那些坐位舒张压(SDBP)≥95但≤115 mmHg的患者有资格进入为期3周(第-6至-3周)的安慰剂导入期低盐饮食(50至80 mmol Na⁺/天)。然后在安慰剂治疗中加入高盐(200至250 mmol Na⁺/天),持续3周(第-3至0周)。那些从低盐饮食到高盐饮食时SDBP升高≥5 mmHg的患者被认为是盐敏感的,并被随机分为为期4周(第0至4周)的双盲治疗期,分别接受每天两次2.5至10 mg伊拉地平、每天两次2.5至20 mg依那普利或安慰剂治疗。然后他们进入为期3周(第4至7周)的低盐饮食(50至80 mmol Na⁺/天)的安慰剂洗脱期。在第7周之后,且继续低盐饮食的同时,患者重新开始双盲治疗4周(第7至11周),研究结束。在1916名筛查的患者中,464名被随机分配到双盲治疗阶段,397名完成了研究。在高盐饮食期间,伊拉地平和依那普利均降低了坐位收缩压(SSBP)和SDBP,程度相似,而在低盐饮食期间,依那普利导致的SSBP和SDBP降低幅度大于伊拉地平(分别为11.3±1.2/7.7±0.7 mmHg对7.7±0.9/4.8±0.6 mmHg,均值±标准误,P<0.02)。在药物内部,伊拉地平在高盐饮食期间对血压(BP)的影响高于低盐饮食期间(SSBP为14.9±1.5对7.6±1.3 mmHg,SDBP为10.1±0.6对4.8±0.9 mmHg,P<0.001),但依那普利在两种饮食期间发挥的作用相似。由于限盐降低了SSBP和SDBP,两种药物达到的最低血压均出现在限盐阶段。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验